Shares of BioLineRx (BLRX) trade 12% higher in premarket action.
Data presented at ASH show BL-8040 "is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model."
Here's CEO Kinneret Savitsky: "The results presented ... show that BL-8040 is highly effective in directly inducing AML cell death and in augmenting the effects of other drugs, resulting in an exceptionally high percentage of cell growth inhibition and death."
The company says "synergistic effects" were observed when BL-8040 was combined with quizartinib. (PR)